Q1 FY27 Results Presentation
Released
Released
Announcement PDF
1
ATOMO
DIAGNOSTICS
1Q 2027 RESULTS OVERVIEW
29 OCTOBER 2026
2
This presentation has been prepared by Atomo Diagnostics Limited (“Atomo”) based on
information available as at the date of this presentation. The information in this presentation is
provided in summary form and does not contain all information necessary to make an investment
decision. Reliance should not be placed on the information or opinions contained in this
presentation. An investor must not act on the basis of any matter contained in this presentation
but should make its own assessment of Atomo as part of its own investigations.
This presentation has been provided for general information purposes only. It does not constitute
an offer, invitation, solicitation or recommendation with respect to the purchase or sale of any
security in Atomo, nor does it constitute financial product advice or take into account any
individual’s investment objectives, taxation situation, financial situation or needs.
Although reasonable care has been taken to ensure that the facts stated in this presentation are
accurate and that the opinions expressed are fair and reasonable, no representation or warranty,
express or implied, is made as to the fairness, accuracy, completeness or correctness of the
information, opinions and conclusions contained in this presentation. To the maximum extent
permitted by law, neither Atomo, nor any of its officers, directors, employees and agents, nor any
other person, accepts any responsibility or liability for the content of this presentation including,
without limitation, any liability arising from fault or negligence, for any loss arising from the use of
or reliance on any of the information contained in this presentation or otherwise arising in
connection with it. This disclaimer also extends to all and any information and opinions contained
in, and any omissions from, any other written or oral communications transmitted or otherwise
made available to the recipient in connection with the opportunity outlined in this presentation and
no representation or warranty is made in respect of such information.
The information presented in this presentation is subject to change without notice and Atomo does
not have any responsibility or obligation to inform you of any matter arising or coming to their
notice, after the date of this presentation, which may affect any matter referred to in this
presentation. The cover image is illustrative only.
This presentation may contain certain forward-looking statements that are based on Atomo’s
beliefs, assumptions and expectations and on information currently available to Atomo
management. Such forward looking statements involve known and unknown risks, uncertainties,
and other factors which may cause the actual results or performance of Atomo to be materially
different from the results or performance expressed or implied by such forward looking
statements. Such forward looking statements are based on numerous assumptions regarding
present and future business strategies and the business, economic and competitive environment in
which they operate in the future, which are subject to change without notice. Past performance is
not necessarily a guide to future performance and no representation or warranty is made as to the
likelihood of achievement or reasonableness of any forward-looking statements or other forecast.
To the full extent permitted by law, Atomo and its directors, officers, employees, advisers, agents
and intermediaries disclaim any obligation or undertaking to release any updates or revisions to
information to reflect any change in any of the information contained in this presentation
(including, but not limited to, any assumptions or expectations set out in the presentation).
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
DISCLAIMER ASX: AT1
3
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
ATOMO DIAGNOSTICS – 1Q27
Quarterly Highlights
ASX: AT1
Transitioning to sustainable revenue growth with an expanding new product pipeline
PIPELINE MILESTONES COMMERCIAL PERFORMANCE
Upfront Diagnostics + Atomo partnership
Next-generation rapid Pre-Hospital LVTWO Brain Disease Test.
Generation 4 HIV development agreement
With Innovation Scientific PTY LTD, adding to Atomo’s
proprietary product development pipeline.
Active Syphilis transfers to manufacturing
Preparation progresses for clinical trials to begin in the new
calendar year.
$1.63m
TOTAL Q1 2027 REVENUE
140% quarter-on-quarter
$939k
FEBRIDX®/OEM REVENUE
469% quarter-on-quarter
$2.51m
CASH RECEIPTS
$2.40m from customer receipts + $84k CRC-P Active Syphilis
grant; $2.67m quarter-end cash
Q1 PERFORMANCE
HIV SALES GROWTH | YOY
+38.3%
Q1 FY27 versus Q1 FY26
HIV SALES
Q1 FY26 $456k
Q1 FY27 $630k
WHERE Q1 SALES CAME FROM
INTERNATIONAL | VIATRIS
Increased HIV test supply to Viatris Healthcare (Pty) Ltd through the existing
international partner relationship.
+39.5%
ANZ PHARMACY SALES QOQ
Australian wholesalers +41.3%
New Zealand retail +30.3%
ADDITIONAL HEALTH & COMMUNITY SUPPLY
Existing ANZ health and community accounts placed further orders.
Overall HIV Growth International and ANZ pharmacy channels outperformed to deliver 38.3% year-on-year HIV sales growth.
ASX: AT1
Global sales growth in HIV franchise led by International supply and ANZ pharmacy channels
HIV Q1 REVENUE PERFORMANCE ASX: AT1
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 4
ATOMO OEM PERFORMANCE | Q1 Q-ON-Q
+469%
OEM SALES REVENUE
A$165k → A$939k
+713%
GROWTH IN DEVICES SUPPLIED
US FEBRIDX® ADOPTION | LUMOS-REPORTED
215 LIVE US SITES
September 2026
+26.5% 170 in July → 215 in September
405 sites under evaluation (350 in July)
March 2026 FDA CLIA waiver expanded eligible US testing settings.
OEM momentum Flu-season inventory build fuels triple-digit revenue and device-volume growth.
Strong QOQ growth driven by Lumos Diagnostics’ FebriDx
PASCAL OEM Q1 REVENUE PERFORMANCE
ASX: AT1
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 5
ASX: AT1
Global licence, development and supply agreement with Innovation Scientific
GEN 4 HIV PARTNERSHIP OPENS A NEW COMMERCIAL PATH
ASX: AT1
THE MOU AGREEMENT
Atomo to receive a
global licence to
commercialise a rapid
Gen 4 HIV assay in its
Galileo cassette.
Feasibility testing complete. The
partnership now moves into
final analytical/clinical studies and
regulatory preparation.
Parties to negotiate final Supply
Agreement and Licence over next
four months.
WHO DOES WHAT
INNOVATION SCIENTIFIC
— Complete final assay development
— Run analytical and clinical studies with Atomo
— Integrate Galileo sub-assemblies with the strip and
buffer for finished supply
ATOMO
— Hold the global assay licence and act as legal
manufacturer
— Lead IVDR and TGA registration, launch and
commercialisation
COMMERCIAL PATH
18 MONTHS
Planned IVDR and TGA registration window
24 MONTHS
Target timing for commercial launch
A$1.16bn
HIV global rapid-test kit market
STRATEGIC FIT Extends Atomo’s Gen 3 HIV + Active Syphilis portfolio; own-pipeline revenue is targeted from late FY2028.
Manufacture and supply Galileo sub-assemblies
—
Source: Future Market Insights, 2026; Market Glass, Inc., 2026;
MarketsandMarkets, 2025
6
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
GEN 3 | ESTABLISHED - SELF-TEST GEN 4 | NEW PRODUCT - PROFESSIONAL TEST
FORMAT Antibody-based HIV self-test
OPERATOR Individual self-tester
CHANNELS Pharmacy, community, public health, rapid screening
POSITION Existing self-testing routes and programs
FORMAT Proposed rapid antigen/antibody test
OPERATOR Clinicians and trained professionals
CHANNELS Sexual health, primary care, clinical POC
FOCUS MARKETS Europe/UK, ANZ, APAC, USA
INDICATIVE GLOBAL MARKET CONTEXT | DISTINCT 2025 CATEGORY ESTIMATES
A$4.62bn
All HIV diagnostics
A$1.16bn
HIV rapid-test kits
A$341m
HIV self-testing
Source: Future Market Insights, 2026; Market Glass, Inc., 2026; MarketsandMarkets, 2025
WHAT GEN 4 BRINGS
Expands professional-use buyers, clinical uses and procurement pathways beyond self-testing; overlap remains possible in assisted testing.
Potential as market evolves to support ongoing Pre-Exposure Prophylaxis (PrEP) treatment. PrEP is a prescription medicine taken by HIV-
negative people to lower the risk of getting HIV.
ASX: AT1
Large and growing market opportunity for Atomo’s expanding HIV franchise
HIV RAPID TESTING MARKET: GEN 4 and GEN 3 ASX: AT1
MARKETS Europe, UK, ANZ, LMIC, Others
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 7
ASX: AT1
Upfront’s biomarker assay moves into Atomo’s technology platform
UPFRONT + ATOMO PARTNER ON NEXT-GENERATION TEST ASX: AT1
LVTwo
A rapid blood-based brain-disease test
designed for use before hospital arrival—
helping emergency teams triage suspected
stroke or other brain disease patients
sooner.
PARTNERSHIP ANNOUNCEMENT
Atomo and Upfront announce partnership for Upfront’s
next-generation test in Atomo’s device.
DETECT
Proprietary biomarker
targets proteins associated
with brain disease.
DEPLOY
Atomo hand-held devices
combine blood collection,
sample transfer and buffer
delivery.
DECIDE EARLIER
Designed for pre-hospital
use to support faster
routing and treatment
decisions.
9,000 Atomo sub-assemblies supplied for validation and verification
activities to date
8
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Sources: Feigin et al. (2025); Stroke Foundation (2024); Stroke Aotearoa NZ; Christensen et al. (2026); CDC (2024). Regional data use different years and methodologies and do not represent addressable test demand.
ASX: AT1
BRAIN DISEASE BURDEN CREATES A SCALABLE TRIAGE OPPORTUNITY
ASX: AT1
GLOBAL CLINICAL NEED
11.9 million
new strokes worldwide annually
A large, time-critical patient population
creates demand for tools that can support
earlier stroke triage and routing decisions
before hospital arrival.
REGIONAL MARKETS
54,800
AUSTRALIA + NEW
ZEALAND
estimated stroke events
per year
Australia 45,785 + NZ
9,000
1.46m
EUROPE
reported stroke events
47 reporting areas · 2023
795,000+
UNITED STATES
estimated strokes each
year
≈610k first · ≈185k
recurrent
Pre-hospital stroke
triage
D-dimer + GFAP
assay validation
OEM supply as
adoption scales
PATHWAY FROM CLINICAL NEED TO REGULATORY APPROVAL AND GLOBAL SALES
SUSPECTED BRAIN DISEASE TRIAGE INDICATION
Ambulance / emergency department
VALIDATED RAPID ASSAY
Evidence, approval and clinical adoption
GLOBAL REGULATORY APPROVALS
Gateway to commercial sales
→ →
The partnership will provide a new revenue stream for a significant and exciting new clinical indications
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 9
ACTIVE SYPHILIS TRANSFERS TO MANUFACTURING ASX: AT1
Program remains on schedule, with regulator engagement beginning and launch targeted within 18–24 months
10
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
TEST DIFFERENTIATION
15 MINUTES
Rapid lateral flow test for home-
based and healthcare-practitioner-
guided self-testing.
ADDRESSES A KEY TESTING GAP
Designed to detect infectious
syphilis and distinguish active
cases from previously treated
cases.
EARLY CLINICAL PERFORMANCE
100%
SENSITIVITY
against active syphilis
samples by clinical history
99%
SPECIFICITY
against never-infected
patients
93%
SPECIFICITY
against previously treated
cases with clinical history
Early clinical testing; results reported by clinical
history.
PROGRAM ON SCHEDULE
TRANSFER COMPLETE
Test-strip manufacturing moved from Burnet
Institute in Melbourne to Cape Town for clinical-
trial production builds.
NEXT: CLINICAL TRIALS
Trials expected to commence early next year.
REGULATORY + LAUNCH
Engagement planned with TGA, FDA and BSI;
commercial launch targeted within 18–24
months.
ASX: AT1
Commercial products fund a broader portfolio progressing through validation, development and feasibility
ATOMO PROPRIETARY PRODUCT PIPELINE ASX: AT1
Proprietary portfolio spans established revenue products and new tests targeting decentralised professional and self-test markets.
PRODUCT / APPLICATION
FEASIBILITY DEVELOPMENT VALIDATION COMMERCIAL
HIV GEN 3 HIV screening / self-test
COMMERCIAL
HIV GEN 4 Antibody + p24 antigen
DEVELOPMENT
ACTIVE SYPHILIS Active vs treated infection
VALIDATION
LIVER / ALT Liver health screening
DEVELOPMENT
HCV Hepatitis C virus
FEASIBILITY
HBV Hepatitis B virus
FEASIBILITY
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 11
ASX: AT1
Atomo technology enables partner assays to move from technical validation into commercial supply at scale
OEM PARTNER PIPELINE ASX: AT1
OEM pipeline focused on professional point-of-care markets and scalable partner supply.
PRODUCT / APPLICATION
FEASIBILITY DEVELOPMENT VALIDATION COMMERCIAL
FEBRIDX® Lumos · acute respiratory
infection
COMMERCIAL
FERRITIN Chromacare · iron deficiency
VALIDATION
BRAIN DISEASE Upfront · pre-hospital triage
VALIDATION
Atomo technology platforms support multiple partner assays—creating recurring device-supply opportunities as programs progress.
PREGNANCY NG Biotech · early pregnancy
detection
COMMERCIAL
12
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
1Q27 – PROFIT & LOSS
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Revenue and gross profit increased strongly year-on-year
* Amounts in A$'000; YoY compares Q1 FY27 (unaudited) with Q1 FY26
A$'000 1Q FY27 1Q FY26 YoY change
Revenue 1,628 680 +140%
Cost of sales (1,204) (424) +184% cost
Gross profit 424 256 +66%
Gross margin 26% 38% -11.6 pts
Other income 217 68 +221%
Operating expenditure (1,979) (1,307) +51% cost
EBITDA (1,337) (983) +36% loss
PBT (1,627) (1,368) +19% loss
REVENUE
$1.63m
1Q FY26 $0.68m
+140% YoY
GROSS PROFIT
$0.42m
1Q FY26 $0.26m
+66% YoY
GROSS MARGIN
26%
1Q FY26 38%
-11.6 pts YoY
EBITDA
($1.34m)
1Q FY26 ($0.98m)
+36% loss YoY
13
14
1Q27 – BALANCE SHEET
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
1Q FY27 closes with $2.67m in cash, $9.63m in assets and no bank debt
* Amounts in A$'000; September 2026 (unaudited) actuals
A$'000 1Q FY27
Cash and cash equivalents 2,669
Trade and other receivables 1,301
Inventories 1,723
R&D tax rebate receivable 1,075
Prepayments 327
Total current assets 7,140
Property, plant and equipment 295
Right-of-use assets 297
Intangible assets 823
Development costs 1,070
Total non-current assets 2,485
Total assets 9,625
Total liabilities 3,479
Net assets 6,145
Total equity 6,145
CASH
$2.67m
available liquidity
TOTAL ASSETS
$9.63m
as at September 2026
NO DEBT
$0
bank borrowings
1Q27 – CASH FLOW
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
Q1 FY27 ended with $2.67m in cash after a $1.01m net cash outflow
* Amounts in A$'000; September 2026 YTD (unaudited) actuals
A$'000 Q1 FY27
Receipts from customers 2,401
Payments to suppliers and employees (3,437)
Interest received 23
Grant funds received from CRC-P 84
Net cash used in operating activities (929)
Property, plant and equipment purchases (17)
Net cash used in investing activities (17)
Finance lease repayments (69)
Net cash used in financing activities (69)
Net decrease in cash (1,014)
Cash at beginning of period 3,709
Exchange losses (25)
Cash at end of period 2,669
CASH AT END
$2.67m
September 2026
CUSTOMER RECEIPTS
$2.40m
1Q FY27 YTD
15
16
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1)
BUILDING A STRONGER BASE FOR SCALABLE GROWTH
Commercial momentum is funding a broader product pipeline and a more diversified revenue base
$1.63m
HIV franchise +38.3% QoQ
OEM revenue $938k, up 469% QoQ
HIV FRANCHISE LEADS COMMERCIAL TRACTION
HIV sales increased 38.3% year on year, led by international supply and
ANZ pharmacy channels.
FEBRIDX® SHOWS THE POWER OF THE OEM MODEL
FebriDx® revenue reached $683k, up 314% year on year, while device supply
increased 501%.
DIVERSIFICATION BUILDS OVER TIME
HIV, pregnancy, and FebriDx® provide the commercial base as the
proprietary pipeline and OEM programs in syphilis, Gen 4 HIV, stroke,
ferritin, and earlier-stage assays advance.
A stronger HIV franchise and scalable OEM model support a broader, more diversified growth platform over time.
1Q REVENUE | +140% QoQ
: AT1
For further information, please contact:
Cheri Walker, Interim CEO and Executive Director
Cheri.Walker@atomodiagnostics.com
p. +61 2 9099 4750
Investor Queries Investorqueries@atomodiagnostics.com
Atomo Q1 FY27 Quarterly Investor Webinar Presentation
Atomo Diagnostics Limited will hold its Q1 FY27 Quarterly Investor Webinar on Tuesday 03rd November
2026 at 2pm (AEDT).
To access the webinar, please pre-register by clicking this link
To access Atomo’s Investor Hub, please scan the QR code or visit
https://investors.atomodiagnostics.com/auth/signup
ATOMO DIAGNOSTICS LIMITED | (ASX: AT1) 17
Share your feedback
Discover